Cingulate Inc (CING)
$5.92
Performance
- $5.30$6.19$5.92
10.47%
Downside
Day's Volatility :14.36%
Upside
4.34%
- $1.80$187.20$5.92
69.59%
Downside
52 Weeks Volatility :99.04%
Upside
96.84%
Returns
| Period | Cingulate Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -31.75% | 0.0% |
6 Months | -58.54% | 0.0% |
1 Year | -95.52% | 0.0% |
3 Years | -99.45% | -22.3% |
Highlights
Market Capitalization | 10.4M |
Book Value | $3.95 |
Earnings Per Share (EPS) | -326.4 |
Wall Street Target Price | 135.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -225.77% |
Return On Equity TTM | -1364.73% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -9.0M |
EBITDA | -18.0M |
Diluted Eps TTM | -326.4 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -18.68 |
EPS Estimate Next Year | -24.56 |
EPS Estimate Current Quarter | -5.64 |
EPS Estimate Next Quarter | -5.4 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 2185.98%
Technicals Summary
Sell
Neutral
Buy
Cingulate Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cingulate Inc | 81.97% | -58.54% | -95.52% | -99.45% | -99.45% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cingulate Inc | NA | NA | NA | -18.68 | -13.65 | -2.26 | NA | 3.95 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cingulate Inc | Buy | $10.4M | -99.45% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Cingulate Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 132.6%
Institutional Holdings
Armistice Capital, LLC
2.36%Commonwealth Equity Services Inc
0.53%COWEN AND COMPANY, LLC
0.46%HRT FINANCIAL LLC
0.05%Tower Research Capital LLC
0.04%Bank of America Corp
0.01%
Company Information
Organization | Cingulate Inc |
Employees | 13 |
CEO | Dr. Shane J. Schaffer Pharm.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$5.92
-1.66%
Keyarch Acquisition Corp
$5.92
-1.66%
Connexa Sports Technologies Inc
$5.92
-1.66%
Us Value Etf
$5.92
-1.66%
First Wave Biopharma Inc
$5.92
-1.66%
Global X Msci Next Emerging
$5.92
-1.66%
Fat Projects Acquisition Corp
$5.92
-1.66%
Capital Link Global Fintech
$5.92
-1.66%
Applied Uv Inc
$5.92
-1.66%